Last reviewed · How we verify
DCR-HBVS
At a glance
| Generic name | DCR-HBVS |
|---|---|
| Also known as | DCR-S219 |
| Sponsor | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DCR-HBVS CI brief — competitive landscape report
- DCR-HBVS updates RSS · CI watch RSS
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company portfolio CI